SOURCE: Integrated Diagnostics

Integrated Diagnostics

February 03, 2015 09:30 ET

Indi® Announces Agreement to License Xpresys® Lung in Canada to Caprion

SEATTLE, WA--(Marketwired - Feb 3, 2015) - Indi (Integrated Diagnostics®) today announced an exclusive agreement to license Xpresys Lung in Canada to Caprion. Xpresys Lung is Indi's breakthrough, molecular diagnostic blood test designed to provide physicians with an objective tool to address a major medical dilemma -- the management of indeterminate lung nodules. The test, currently only available as a clinical laboratory developed test in the United States, provides physicians with objective information to identify nodules with a high probability of being benign. It aims to reduce unnecessary invasive procedures, which may be risky for the patient and costly to the healthcare system.

"We are delighted that Xpresys Lung's game-changing patient benefits and healthcare cost savings will be coming to Canada," said Albert A. Luderer, Ph.D., chief executive officer, Indi. "Indi's agreement enables Caprion to deploy our proven, standardized proteomic technology platform by building and operating their own Xpresys Lung laboratory service -- equivalent to our CLIA laboratory in the U.S. We see this as an important model for future international deployment of Xpresys Lung."

The agreement marks the continuation of a long-standing collaboration between the two companies that began with Caprion acting as an early partner of Indi's in the clinical discovery of Xpresys Lung.

"Xpresys Lung is an important addition to our laboratory service business and enables us to help physicians in Canada reduce the need for unnecessary invasive procedures for indeterminate lung nodules -- reducing risk and anxiety for patients, and generating economic efficiencies for our healthcare system," said Martin LeBlanc, chief executive officer, Caprion. "We look forward to offering Canadian physicians and patients access to this cutting-edge molecular diagnostic test from our laboratory in Montreal."

Caprion will hold the exclusive rights to market and commercialize Xpresys Lung in Canada, beginning with Quebec. Indi's CLIA certified clinical laboratory in Seattle will continue to perform all analysis for the U.S. market. Caprion will pay Indi royalties and several milestone payments. Exact financial terms of the agreement were not disclosed.

Caprion has received support in its Canadian commercial development efforts for Xpresys Lung from the Government of Québec as part of the Personalized Medicine Partnership for Cancer (PMPC), a public-private partnership led by Caprion that is focused on the development and implementation of clinical biomarkers and personalized healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients in the province of Québec.

About Xpresys Lung

Xpresys Lung is a breakthrough protein expression blood test developed to provide physicians with a solution to a major medical dilemma -- the overtreatment of benign lung nodules. Today, it is estimated millions of pulmonary nodules are discovered each year; after traditional assessment protocols, which include biopsies and surgeries, most of these nodules are classified as benign. Xpresys Lung allows for the non-invasive assessment of pulmonary nodules in the 8-30 mm size range; traditionally, nodules of this size are associated with significant diagnostic uncertainty.

The blood test measures the relative abundance of proteins from multiple pathways associated with lung cancer, using a highly sensitive analytic technique called multiple reaction monitoring mass spectroscopy (MRM-mass spec).

Xpresys Lung is supported by a landmark clinical validation study published in The Journal of Thoracic Oncology in January 2015 and two studies published in Science Translational Medicine on October 2013. Click here to access the STM study.

About Indi

Indi (Integrated Diagnostics) is redefining molecular diagnostics and creating powerful new tools for physicians to non-invasively assess and more effectively manage complex diseases to improve patient outcomes, reduce complications, and lessen costs to the healthcare system. With the company's first breakthrough test, Xpresys Lung, which measures multiple blood proteins and identifies lung nodules with a high probability of being benign, physicians have the potential to reduce risks and the need for unnecessary invasive procedures.

The company was co-founded in October 2009 by systems-biology pioneer Dr. Lee Hood, who recently received the National Medal of Science from the U.S. government. His groundbreaking research is based on a systems biology approach, which measures hundreds of protein biomarkers found in blood to report on the physiological state of the body's 50 major organs, such as the lungs.

Backers include Baird Capital, InterWest Partners, Life Sciences Alternative Financing and the Wellcome Trust. Foundational intellectual property is exclusively licensed from the Institute for Systems Biology and Caltech. Learn more at

About Caprion

Caprion is the leading provider of proteomics and immune monitoring services to the pharmaceutical and biotechnology industry. Caprion uses its proprietary ImmuneCarta©, immune monitoring technology to perform multiparametric flow cytometry for functional analyses of innate and adaptive immune responses. Caprion's proprietary ProteoCarta™ proteomics technology uses gel-free, label-free mass spectrometry (MS) to perform comprehensive, quantitative and robust comparative measurement of proteins across large sets of biological samples. Caprion leverages ProteoCarta for the discovery and validation of protein biomarkers as a service to its multiple industry clients and also to develop its own in-vitro diagnostic products targeting cancer, metabolic and infectious diseases. With research sites in Montreal, Canada and in Menlo Park, CA, Caprion has been providing large-scale proteomics and immune monitoring services to over 50 major pharmaceutical and biotech clients for more than 10 years. Caprion, a privately-held company, is majority owned by Chicago Growth Partners. For more information, please visit

Contact Information


    Eliot Dobris
    Director of Communications
    (415) 902-1241
    Email Contact

    Carol Berry, MBA
    Chief Business Officer, SVP
    (514) 360-3600
    Email Contact